HomeSGMO • NASDAQ
add
Sangamo Therapeutics Inc
Previous close
$0.49
Day range
$0.47 - $0.53
Year range
$0.29 - $1.78
Market cap
101.84M USD
Avg Volume
2.05M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 2.04M | -92.50% |
Operating expense | 10.30M | -37.37% |
Net income | -60.30M | -16.01% |
Net profit margin | -2.95K | -1,446.99% |
Earnings per share | -0.34 | -5.57% |
EBITDA | -48.74M | 6.37% |
Effective tax rate | 0.45% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 81.00M | -70.82% |
Total assets | 165.32M | -70.61% |
Total liabilities | 82.43M | -69.19% |
Total equity | 82.89M | — |
Shares outstanding | 178.91M | — |
Price to book | 1.03 | — |
Return on assets | -65.66% | — |
Return on capital | -86.91% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -60.30M | -16.01% |
Cash from operations | -50.54M | 11.41% |
Cash from investing | 37.71M | -11.51% |
Cash from financing | 167.00K | -99.15% |
Net change in cash | -11.31M | -292.54% |
Free cash flow | -28.36M | 33.77% |
About
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases. Wikipedia
CEO
Founded
1995
Headquarters
Website
Employees
405